

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6086672

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
WENBIN LIN	04/06/2019
CHRISTINA CHAN	04/08/2019
WENBO HAN	04/08/2019
RECEIVING PARTY DATA	
Name:	THE UNIVERSITY OF CHICAGO
Street Address:	5801 S. ELLIS AVENUE
City:	CHICAGO
State/Country:	ILLINOIS
Postal Code:	60637
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16859594
CORRESPONDENCE DATA	
Fax Number:	(919)419-0383
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9194938000
Email:	cchia@jwth.com
Correspondent Name:	ARLES A. TAYLOR, JR.
Address Line 1:	3015 CARRINGTON MILL BOULEVARD
Address Line 2:	SUITE 550
Address Line 4:	MORRISVILLE, NORTH CAROLINA 27560
ATTORNEY DOCKET NUMBER:	3072/12/3 DIV
NAME OF SUBMITTER:	CONSTANCE CHIA
SIGNATURE:	/constance chia/
DATE SIGNED:	04/30/2020
Total Attachments: 3	
source=Executed_Assignment_3072-12-2#page1.tif	
source=Executed_Assignment_3072-12-2#page2.tif	
source=Executed_Assignment_3072-12-2#page3.tif	

ASSIGNMENT

Pursuant to our obligation to THE UNIVERSITY OF CHICAGO ("ASSIGNEE"), an Illinois not for profit corporation having its principal place of business at 5801 S. Ellis Avenue, Chicago, Illinois 60637, and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we:

WENBIN LIN

CHRISTINA CHAN

WENBO HAN

confirm that we have sold, assigned, and conveyed unto ASSIGNEE, its successors and assigns, or to the extent we have not yet sold, assigned or conveyed, do hereby sell, assign and convey unto ASSIGNEE, its successors and assigns, our entire right, title, and interest -

(1) in and to an invention entitled "Combination of Micheliolide Derivatives or Nanoparticles with Ionizing Radiation and Checkpoint Inhibitors for Cancer Therapy" [UCHI 2821/18-T-036] ("INVENTION") for which we have filed United States Provisional application 62/657,112 entitled "**COMBINATION OF MICHELIOLIDE DERIVATIVES OR NANOPARTICLES WITH IONIZING RADIATION AND CHECKPOINT INHIBITORS FOR CANCER THERAPY**" on April 13, 2018; and

(2) in and to said United States patent applications, in and to all other patent applications (including additional Provisionals, US Utility, PCT, divisional, continuation, continuation-in-part, §111(b) provisional, §111(a), and reissue applications) based upon said invention, including the right to claim priority to said Provisional patent application and to all other applications based



upon said invention, and in and to the patent or patents to be granted thereon, including reissues thereof, if any, to the full end of the term or terms for which said patent or patents may be granted. The effective date of this Assignment is April 5, 2018; and

(3) in and to all patent applications based on INVENTION now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said foreign applications to the full end of the term or terms for which said foreign patents may be granted; AND

(4) in and to the right to claim the full benefits and priority rights under the International Convention (and any other international agreement to which the United States adheres) in and to any and all patent applications -- both United States and foreign patent applications -- based on INVENTION now or hereafter filed.

And we hereby agree that, under the International Convention, any United States patent application(s) and any foreign application(s) which may be filed shall be filed in the name of ASSIGNEE with a claim to priority based on said United States Application.

And we hereby agree that we will, upon request of ASSIGNEE, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary -- or deemed by ASSIGNEE, its successors or assigns, to be necessary -- to a complete fulfillment of the intents and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by ASSIGNEE, its successors or assigns, and not by us.

And the Commissioner of Patents and Trademarks of the United States is hereby
authorized and requested to issue said United States patent or patents to ASSIGNEE.

April 6, 2019
Date

April 6, 2019
Date

April 8, 2019
Date

April 8, 2019
Date

April 8, 2019
Date

April 8, 2019
Date

ACCEPTED:

April 9, 2019
Date

[Signature]
Wenbin Lin

Guangxu Lan
Witness Signature

Guangxu Lan
Witness Printed Name

[Signature]
Christina Chan

[Signature]
Witness Signature

Nining Guo
Witness Printed Name

[Signature]
Wenbo Han

[Signature]
Witness Signature

Xiaomin Jiang
Witness Printed Name

[Signature]
Cristianne Frazier
Assistant Director
Polksy Center for Entrepreneurship and Innovation,
The University of Chicago

PATENT